Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Niraparib Individualized Starting Dose Tolerable in Platinum-Sensitive Recurrent Ovarian Cancer

June 5th 2021

Niraparib, when delivered at an individualized starting dose, was found to be well tolerated in patients with platinum-sensitive recurrent ovarian cancer.

Dr. Chern on Future Research Directions in Ovarian Cancer

May 25th 2021

Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.

FDA Grants Breakthrough Therapy Designation to VS-6766/Defactinib for Recurrent Low-Grade Serous Ovarian Cancer

May 24th 2021

The FDA has granted a breakthrough therapy designation to VS-6766 plus defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer, irrespective of KRAS status, following 1 or more previous lines of therapy, including platinum-based chemotherapy

Dr. Monk on Guidelines for Maintenance PARP Inhibitors in Ovarian Cancer

May 19th 2021

Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.

Molecular Markers and Prior Treatment Inform Maintenance PARP Inhibition in Ovarian Cancer

May 11th 2021

Bradley J. Monk, MD, FACOG, FACS, discusses findings from key studies that solidified the role of PARP inhibition as maintenance therapy for patients with ovarian cancer, as well as guidelines for selecting PARP inhibitors alone or in combination with bevacizumab.

ARIEL2 Analysis Sheds Light on Biomarkers of Response to Rucaparib in Ovarian Cancer

May 4th 2021

RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.

Dr. Miller on the Potential Utility of Sequential PARP Inhibition in Ovarian Cancer

April 27th 2021

Eirwen M. Miller, MD, discusses the potential utility of sequential PARP inhibition in ovarian cancer.

Bringing Individualized Care to Patients With Breast and Ovarian Cancers in the Caribbean

April 26th 2021

Current breast cancer screening practices in the Caribbean exclude the majority of the younger patient population, thereby leaving many cases of breast cancer undiagnosed.

Unique Landscape of Actionable Pathogenic Variants Unfolds in Breast and Ovarian Cancers in the Caribbean

April 16th 2021

Sophia George, PhD, and Judith E. Hurley, MD, discuss the importance of the genetic association study, challenges faced with launching such an effort, the key findings from the research, and the clinical implications of the data in the Caribbean as well as the United States

Pursuing PARP Beyond HRD+ Ovarian Cancer

April 9th 2021

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

Utility of HRD Testing in Ovarian Cancer Expands, but Standardization Remains Elusive

April 6th 2021

Thomas C. Krivak, MD, discusses the significance of HRD in ovarian cancer, approved and prospective HRD tests, and considerations for genomic testing in this population.

Dr. Nakayama on Using Precision Medicine With Mirvetuximab Soravtansine in Ovarian Cancer

April 5th 2021

John Nakayama, MD, discusses the potential utility of precision medicine with mirvetuximab soravtansine in ovarian cancer.

Dr. Miller on Approaching Frontline Maintenance Therapy in Ovarian Cancer

April 2nd 2021

Eirwen M. Miller, MD, discusses her approach to frontline maintenance therapy in ovarian cancer.

Study Examines Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer

April 2nd 2021

Out-of-pocket costs for patients with ovarian cancer who have been treated with PARP inhibitors are generally low, according to recent study results from a single institution.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Dr. Wenham on Future Directions with Antibody-Drug Conjugates in Ovarian Cancer

March 30th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Mirvetuximab Soravtansine/Rucaparib Shows Early Tolerability, Activity in Ovarian and Endometrial Cancers

March 29th 2021

The combination of mirvetuximab soravtansine and rucaparib was found to be well tolerated, with encouraging activity reported in heavily pretreated patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer

March 25th 2021

Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.

Farletuzumab/Chemo Fails to Improve PFS in Platinum-Sensitive, Recurrent Ovarian Cancer With Low CA-125

March 25th 2021

The addition of farletuzumab to carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin did not demonstrate superiority over placebo plus chemotherapy in patients with platinum-sensitive recurrent ovarian cancer who are in their first relapse and have low cancer antigen-125 levels.

Mirvetuximab Soravtansine Monotherapy Under Exploration in Platinum-Resistant FRα+ Ovarian Cancer

March 25th 2021

The exploration of mirvetuximab soravtansine as a potentially efficacious treatment in patients with advanced, high-grade, platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor–alpha expression continues with the ongoing, single-arm, phase 3 SORAYA trial.